Regeneron Says Liver-Fat Drug Cut Fat About 70% In 12 Weeks — 'Game-Changing, Unprecedented'

Regeneron's chief scientist called first-in-human data for a MASH siRNA unprecedented, with more promised at a November 10 investor event.

Share
Regeneron Says Liver-Fat Drug Cut Fat About 70% In 12 Weeks — 'Game-Changing, Unprecedented'

Regeneron Chief Scientific Officer George Yancopoulos said on the company's third-quarter earnings call Friday that a single dose of its experimental liver-disease drug cut liver fat by approximately 70% on average in 12 weeks, results he called "game-changing, unprecedented."

The MASH data from 40 participants

Regeneron, a biotechnology company whose medicines include Dupixent, Eylea HD and Libtayo, is developing an siRNA (a gene-silencing drug) aimed at the Side B gene for MASH, a fatty liver disease. In first-in-human data from 40 participants, Yancopoulos said, one dose was well tolerated and reduced liver fat about 70% from baseline in 12 weeks.

Mean liver fat reached near or below the upper limit of normal at every dose level tested, he said. The effect lasted through 24 weeks of follow-up, with improvements in liver enzymes consistent with less liver cell injury.

Asked by an analyst how it stacks up against other MASH approaches, he said the speed and depth of the reduction were unprecedented. "There's nothing like this before for this disease," he said. The Side B target came from Regeneron's genetics center, which found that people with naturally occurring loss-of-function variants have lower risk of fatty liver disease and cirrhosis.

CEO Leonard Schleifer said the company is moving the program rapidly into registration-enabling studies. First-in-human data will be presented at the liver meeting in November, and Regeneron will say more at its investor roundtable on November 10.

Questions pointed to November 10

An analyst from Barclays asked about fibrosis, cirrhosis versus earlier-stage disease, and FDA endpoints for registrational trials. Yancopoulos said the question was hard to hear, answered on the genetics and said the company would give far more detail at the roundtable.

A separate question, from a BMO Capital Markets analyst, on what unmet need four next-generation Sanofi alliance antibodies address, got a different answer. Schleifer said the call was not the format to unveil that strategy and pointed to a better venue with Sanofi.

A quarter that set the stage

Regeneron's third-quarter revenue grew 36% to $5.1 billion, and non-GAAP earnings per share rose 70% to $20.07. Shares were up about 13% to $928.54 in Friday morning trading, giving a market value of $84.3 billion.

Chief Financial Officer Chris Fenimore said Regeneron expects to book the full $1 billion upfront payment from Sanofi under the expanded antibody alliance as collaboration revenue in the fourth quarter. He said the company generated $2.9 billion of free cash flow in the first nine months of 2026.

Next on the calendar: an FDA decision in November on simdisiran for generalized myasthenia gravis, and the November 10 roundtable.

Sources

More on Regeneron Pharmaceuticals

All Regeneron Pharmaceuticals (REGN) coverage →